Reuters logo
BRIEF-Epizyme says tazemetostat shows clinically meaningful activity
May 18, 2017 / 10:09 AM / 5 months ago

BRIEF-Epizyme says tazemetostat shows clinically meaningful activity

May 18 (Reuters) - Epizyme Inc:

* Epizyme announces path toward Tazemetostat registration in Epithelioid sarcoma and reports new clinical data to be presented at ASCO

* Says Tazemetostat demonstrates clinically meaningful activity in Epithelioid sarcoma

* Says based on discussions with fda, company has identified a path to submission for accelerated approval of Tazemetostat

* Says will target a new drug application (NDA) submission in 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below